Two recent studies demonstrate the joint-protective effects of AmLexin
Two recent studies show that AmLexin may reduce delayed onset muscle soreness and protect cartilage from degradation.
Photo © Shutterstock.com/Sebastian Kaulitzki
Two recently published studies demonstrate the potential benefits of AmLexin (by Unigen; Tacoma, WA), a standardized blend of heartwood of Acacia catechu and the root bark of Morus alba. In a study published in the Journal of Exercise Nutrition & Biochemistry1, the supplement was shown to reduce delayed onset muscle soreness. In the 9-week, double-blind, placebo-controlled clinical trial, 26 subjects were randomized to receive either 400 mg of Amlexin per day or placebo for 8 weeks during a training program, and for one week following a 13.1 mile half-marathon.
Results showed that subjects taking AmLexin experienced significantly lower levels of post-exercise pain one to three days following the half-marathon, compared to placebo. Additionally, those subjects experienced lower post-exercise oxidative stress and higher antioxidant capacity on days one and six following the half marathon.
A different pre-clinical study published in Nutrients2 explored the effects of AmLexin on inflammation and cartilage protection in rats with collagen induced arthritis. “Wear and tear of joint is characterized by progressive depletion of articular cartilage,” explained Qi Jia, PhD, Unigen’s chief scientific officer, in a press release. “Although there have been significant advances in scientific understanding of the cause of such loss of cartilage structure integrity and function, to date, there are no effective options to modify the progression of the depletion of articular cartilage. We believe these unmet needs could be bridged by nutrients and bioactive natural products.”
To this end, AmLexin may play a role. Results from the Nutrients study showed that the rats supplemented with AmLexin experienced a statistically significant reduction in joint symptomatic severity as well as improvements in catabolic biomarkers such as the collagen degradation biomarker uCTXII, and the inflammatory biomarkers IL-beta, TNF-alpha, and IL-6.
References:
1. Yimam M et al. “AmLexin, a Standardized blend of Acacia catechu and Morus alba, shows benefits to delayed onset muscle soreness in healthy runners.” Journal of Exercise Nutrition & Biochemistry, vol. 22, no. 4 (2018)
2. Yimam M et al. “UP1306: A composition containing standardized extracts of Acacia catechu and Morus alba for arthritis management.” Nutrients, vol. 11, no. 2 (2019): 272
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
Arla Foods to acquired whey nutrition business from Volac International
April 22nd 2024Arla Foods Ingredients has reached an agreement to acquire Volac’s Whey Nutrition business through a purchase of shares in Volac Whey Nutrition Holdings Limited and its subsidiary, Volac Whey Nutrition Limited and Volac Renewable Energy Limited.
